Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

This study will assess the effectiveness and safety of pasireotide long-acting release in patients who have rare tumors of neuroendocrine origin.

Principal Investigator

Stanford Investigator(s)

CONTACT INFORMATION

Primary Contact:
Hadar Keren-Gill
(650) 724-4131